ASH: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Acknowledgement of Commercial Support

Supported by an independent medical education grant from Sandoz Inc., a Novartis Division.

ASH: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies


December 8, 2017
7:00PM – 10:00PM
Dinner and registration: 6:00 PM – 7:00PM

Georgia World Congress Center
Dinner: A411-A412
Meeting Room: A402-A403
285 Andrew Young International Blvd NW
Atlanta, GA 30313

Overview:

Many biologic therapies serve as key components of standard-of-care management approaches for patients with hematologic malignancies, including active treatment and supportive care. However, many such biologic options are quite costly, potentially limiting the access of treatments which may improve outcomes for patients with cancer. Biosimilars are biologics that are very similar to the reference biologic products, and they may offer the potential to bridge the treatment gap. Biosimilars require rigorous testing for safety and efficacy before they are approved for the same indication for the reference biologic, and they may help to lower treatment costs for patients with hematologic malignancies.

The process of development, approval, and introduction of a biosimilar agent is quite complex. Regulatory approval for clinical, nonclinical, and analytical comparability to the reference biologic product is essential. Many healthcare providers lack familiarity with this process, as well as safety and efficacy data for biosimilars that are emerging or have already been approved. This interactive symposium will provide clinicians with updates on the latest clinical advancements in biosimilar treatments, including safety and efficacy data pertaining to these treatments. The panel of experts will also address counseling and communication strategies regarding biosimilar agents that may impact patient treatment and management options. Several educational formats will be used, including didactic lecture, case studies, panel discussion, and interactive question and answer sessions.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

After successful completion of this educational activity, participants should be better able to:

  • Describe the developmental process of biosimilars including manufacturing complexities
  • Explain the regulatory process associated with the approval of biosimilars by the FDA, along with the required efficacy and safety data to support a claim that a biosimilar is as safe and effective as the reference product
  • Summarize current and emerging efficacy and safety data for biosimilar agents for the treatment of hematologic malignancies
  • Effectively counsel and communicate the impact biosimilars may have on a patient’s treatment plan, while being able to integrate biosimilars into clinical practice

Activity Chair

Edward Li, PharmD, MPH, BCOP
Professor, Department of Pharmacy Practice
University of New England College of Pharmacy
Portland, ME


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By